Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TLL-018 in Moderate-to-Severe Atopic Dermatitis
NCT07784816Phase 3Not yet recruiting
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Sep 2029
- Countries
- 1
01
Overview
A Phase 3 trial of girocitinib in atopic dermatitis (AD), sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd.. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
girocitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07784816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07784816.